Mirae Asset Sharekhan

DOWNLOAD SHAREKHAN APP

Mirae Asset Sharekhan

OPEN DEMAT ACCOUNT

LOGIN / TRADE OPEN ACCOUNT

Follow Us :

Sharekhan

BUY NOW Buy Kabra Drugs Ltd Stock

Open Free Demat and Trading account in 15 minutes

Overview
Market Data
Market Depth
Option Chain
News
Fundamental
Shareholding Pattern
Corporate Action
Peers
Company Info
FAQ’s

Home Stock Kabra Drugs Ltd

Mon 15/12/2025,11:59:0

NSE

BSE

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 27.82

Previous Close

₹ 28.37

Volume

26723

Mkt Cap ( Rs. Cr)

₹66.38

High

₹ 29.40

Low

₹ 27.52

52 Week High

₹ 32.66

52 Week Low

₹ 10.06

Book Value Per Share

₹ 10.40

Dividend Yield

0.00

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Kabra Drugs Ltd

Your Vote -

Buy

33.33%

Hold

0.00%

Sell

66.67%

33.33%

3 users have voted

No Records Found

Option Chain

Analyzes market sentiment, predicts Kabra Drugs Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

Kabra Drugs Ltd. - Submission Of Notice Of Extra Ordinary General Meeting Under Regulation 30 Of The Securities And Exchange

3 Dec 2025, 12:17PM Notice of Extra Ordinary General Meeting held on 26th December 2025 at Friday.
Kabra Drugs Ltd. - Appointment Of Secretarial Auditor Of The Company

28 Nov 2025, 6:09PM Appointment of Secretarial Auditor of the Company
Kabra Drugs Ltd. - Resignation Of Secretarial Auditor Of The Company

28 Nov 2025, 6:07PM Resignation of Secretarial Auditor of the Company
Kabra Drugs Ltd. - Board Meeting Outcome for Outcome Of Board Meeting Held On 28Th November 2025, As Per Regulation 30 Of SEB

28 Nov 2025, 6:06PM Outcome of Board Meeting held on 28th November 2025, as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Kabra Drugs Ltd. - Board Meeting Intimation for Intimation Of Board Meeting

20 Nov 2025, 1:28PM Kabra Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/11/2025 ,inter alia, to consider and appr
Kabra Drugs Ltd. - Financial Results For The Quarter Ended 30 Th September 2025 Under Regulation 33 Of SEBI (Listing Obligati

13 Nov 2025, 7:06PM Financial result for the quarter ended 30 September 2025
Kabra Drugs Ltd. - Board Meeting Outcome for Outcome Of Board Meeting Held On 13 Th November 2025, As Per Regulation 30 Of\r\

13 Nov 2025, 6:55PM Outcome of Board Meeting held on 13 th November 2025, as per Regulation 30 of\r\nSEBI (Listing Obligations and Disclosure Requirements) Regulations, 2
Kabra Drugs Ltd. - Board Meeting Intimation for Intimation Of Board Meeting

5 Nov 2025, 3:21PM Kabra Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 ,inter alia, to consider and appr
Kabra Drugs Ltd. has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2025

21 Oct 2025, 8:20PM As of September 2025, 100.00% owned by Public. <p align=justify>
Kabra Drugs Ltd. - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

13 Oct 2025, 7:39PM Compliance Certificate under reg. 74 (5) of SEBI (DP) Regulations, 2018
Kabra Drugs Ltd. - Announcement under Regulation 30 (LODR)-Change in Directorate

9 Oct 2025, 1:00PM Change in Directorate
Kabra Drugs Ltd. - Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)

8 Oct 2025, 6:57PM Resignation of CFO
Kabra Drugs Ltd. - Announcement under Regulation 30 (LODR)-Change in Management

8 Oct 2025, 6:56PM Appointment of CFO
Kabra Drugs Ltd. - Announcement under Regulation 30 (LODR)-Change in Directorate

8 Oct 2025, 6:53PM Change in Directorate
Kabra Drugs Ltd. - Announcement under Regulation 30 (LODR)-Resignation of Director

8 Oct 2025, 6:46PM Resignation of Directors
Kabra Drugs Ltd. - Announcement under Regulation 30 (LODR)-Change in Management

8 Oct 2025, 6:44PM Appointment of Directors
Kabra Drugs Ltd. - Board Meeting Outcome for Outcome Of Board Meeting Held On 08 Th October 2025, As Per Regulation 30 Of SEB

8 Oct 2025, 6:40PM Outcome of Board Meeting held on 08 th October 2025, as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Kabra Drugs Ltd. - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

1 Oct 2025, 9:31PM Scrutinizer's Report
Kabra Drugs Ltd. - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

1 Oct 2025, 9:31PM Scrutinizer's Report
Kabra Drugs Ltd. - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

1 Oct 2025, 9:31PM Scrutinizer's Report
Kabra Drugs Ltd. - Shareholder Meeting / Postal Ballot-Outcome of AGM

30 Sep 2025, 9:43AM Outcome and Proceedings of Annual General Meeting
Kabra Drugs Ltd. - Board Meeting Intimation for Intimation Board Meeting Of The Board Of Directors

24 Sep 2025, 5:43PM Kabra Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/10/2025 ,inter alia, to consider and appr

Key fundamentals

Evaluate the intrinsic value of Kabra Drugs Ltd stock

Name	March-25	March-24	March-23	March-22	March-21
Assets	25.0921	2.7913	0.6508	0.6326	0.6927
Liabilities	25.0921	2.7913	0.6508	0.6326	0.6927
Equity	23.7079	4.3886	4.3886	4.3886	4.3886
Gross Profit	-1.718	-0.736	-0.3442	-0.1754	-0.1487
Net Profit	-1.0856	-0.736	-0.3379	-0.1853	-0.18
Cash From Operating Activities	-4.7068	-0.2085	-0.3544	-0.1338	-0.2491
NPM(%)	0	0	0	0	0
Revenue	0	0	0	0	0
Expenses	1.718	0.736	0.3442	0.1754	0.1487
ROE(%)	-4.4	-2.98	-1.37	-0.75	-0.73

Shareholding Pattern

Corporate Action

XD-Date	Dividend-Amount	Dividend-%	Dividend Yield(%GE)	Price on that day

From Year	To Year	Class of Share	Authorized Capital(Crores)	Issued Capital(Crores)	Paid Up Shares(NOS)	Paid Up Face Value	Paid Up Capital(Crores)
2024	2025	Equity Share	40.00	23.71	23707900.00	10	23.71
2023	2024	Equity Share	5.00	4.39	4388600.00	10	4.39
2022	2023	Equity Share	5.00	4.39	4388600.00	10	4.39
2021	2022	Equity Share	5.00	4.39	4388600.00	10	4.39
2020	2021	Equity Share	5.00	4.39	4388600.00	10	4.39
2019	2020	Equity Share	5.00	4.39	4388600.00	10	4.39
2016	2017	Equity Share	5.00	4.39	4388600.00	10	4.39
2015	2016	Equity Share	5.00	4.39	4388600.00	10	4.39
2014	2015	Equity Share	5.00	4.39	4388600.00	10	4.39
2013	2014	Equity Share	5.00	4.39	4388600.00	10	4.39
2012	2013	Equity Share	5.00	4.39	4388600.00	10	4.39
2010	2011	Equity Share	5.00	4.59	4388600.00	10	4.39
2009	2010	Equity Share	5.00	4.59	4388600.00	10	4.39
2008	2009	Equity Share	5.00	4.59	4388600.00	10	4.39
2007	2008	Equity Share	5.00	4.59	4388600.00	10	4.39
2006	2007	Equity Share	5.00	4.59	4388600.00	10	4.39
2005	2006	Equity Share	5.00	4.59	4388600.00	10	4.39
2004	2005	Equity Share	5.00	4.59	4388600.00	10	4.39
1996	2000	Equity Share	5.00	4.59	4388600.00	10	4.39
1995	1996	Equity Share	5.00	4.59	4388600.00	10	4.39
1994	1995	Equity Share	5.00	4.59	4388600.00	10	4.39
1993	1994	Equity Share	5.00	4.39	4388600.00	10	4.39
1992	1993	Equity Share	5.00	1.19	1192300.00	10	1.19
1991	1992	Equity Share	5.00	0.45	450000.00	10	0.45

Announcement Date	Price	Bonus Ratio	Record Date

Fund	Market Value(CR)	% Hold
No Records Found

Peers

Other companies within the same industry or sector that are comparable to Kabra Drugs Ltd

Company	Price	Price (% change)	pe(x)	EV/EBITDA(x)	ROE(%)	ROCE(%)
Albert David Ltd	761.95	-0.75	0.00	16.19	301.39	0.66
Lotus Eye Hospital and Institute Ltd	131.95	2.76	412.44	59.00	3.55	0.00
Bharat Immunological and Biologicals Corporation Ltd	19.20	1.64	0.00	122.50	-39.50	0.00
Astec Lifesciences Ltd	705.40	0.30	0.00	55.64	-604.77	0.00

Company Info

The company Kabra Drugs Ltd was originally incorporated as Pvt. Ltd company on 22.8.1989 and was subsequently converted into a Public Ltd Company on 1.04.1992. The company is coming out with a public issue on 03.03.93 to part finance the expansion project to manufacture pharmaceutical formulations being set up. The first phase of the project i.e,Ether section has already commenced commercial production. The implementation of second phase involving manufacture of injectables is nearing compoletion and the commercial production is likely to be commenced by June 1993. The implementation of the third and last phase has also started. 2014 -Kabra Drugs appointed M/s. M. Maheshwari & Associates, Practicing Company Secretary for Secretarial Audit.

The company Kabra Drugs Ltd was originally incorporated as Pvt. Ltd company on 22.8.1989 and was subsequently converted into a Public Ltd Company on 1.04.1992. The company is coming out with a public issue on 03.03.93 to part finance the expansion project to manufacture pharmaceutical formulations being set up. The first phase of the project i.e,Ether section has already commenced commercial production. The implementation of second phase involving manufacture of injectables is nearing compoletion and the commercial production is likely to be commenced by June 1993. The implementation of the third and last phase has also started. 2014 -Kabra Drugs appointed M/s. M. Maheshwari & Associates, Practicing Company Secretary for Secretarial Audit.

Read More

Parent Organisation

Kabra Drugs Ltd.

Founded

22/08/1989

Managing Director

Mr.N Aravind

NSE Symbol

FAQ

The current price of Kabra Drugs Ltd is ₹ 28.00.

The 52-week high for Kabra Drugs Ltd is

The market capitalization of Kabra Drugs Ltd is currently ₹ 66.38. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Kabra Drugs Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Kabra Drugs Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Kabra Drugs Ltd shares.

The CEO of Kabra Drugs Ltd is Mr.N Aravind, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT